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Abstract
Research on treatments in anorexia nervosa (AN) is scarce. Although most of the therapeutic programs used in ‘real world
practice’ in AN treatment resort to multidisciplinary approaches, they have rarely been evaluated.
Objective: To compare two multidimensional post-hospitalization outpatients treatment programs for adolescents with
severe AN: Treatment as Usual (TAU) versus this treatment plus family therapy (TAU+FT).
Method: Sixty female AN adolescents, aged 13 to 19 years, were included in a randomized parallel controlled trial conducted
from 1999 to 2002 for the recruitment, and until 2004 for the 18 months follow-up. Allocation to one of the two treatment
groups (30 in each arm) was randomised. The TAU program included sessions for the patient alone as well as sessions with a
psychiatrist for the patient and her parents. The TAU+FT program was identical to the usual one but also included family
therapy sessions targeting intra-familial dynamics, but not eating disorder symptoms. The main Outcome Measure was the
Morgan and Russell outcome category (Good or Intermediate versus Poor outcome). Secondary outcome indicators included
AN symptoms or their consequences (eating symptoms, body mass index, amenorrhea, number of hospitalizations in the
course of follow-up, social adjustment). The evaluators, but not participants, were blind to randomization.
Results: At 18 months follow-up, we found a significant group effect for the Morgan and Russell outcome category in favor
of the program with family therapy (Intention-to-treat: TAU+FT :12/30 (40%); TAU : 5/29 (17.2%) p=0.05; Per Protocol
analysis: respectively 12/26 (46.2%); 4/27 (14.8%), p=0.01). Similar group effects were observed in terms of achievement of a
healthy weight (i.e., BMI$10
th percentile) and menstrual status.
Conclusions: Adding family therapy sessions, focusing on intra-familial dynamics rather than eating symptomatology, to a
multidimensional program improves treatment effectiveness in girls with severe AN.
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Introduction
Anorexia Nervosa (AN) is a severe illness affecting 0.5 to 1% of
adolescent females [1–3]. AN has been associated with social
disability [4,5], psychological comorbidity [6,7], physical compli-
cations [8,9], as well as a 10% mortality rate [10]. There is
evidence that the prognosis may be worse in patients for whom
hospitalization is required [11,12].
The research on treatments in AN is scarce. Although most of
the therapeutic programs used in ‘real world practice’ in AN
treatment resort to multidisciplinary approaches, they have rarely
been evaluated [13]. Family therapy (FT) has been reported to be
the most effective treatment for AN adolescents [13–15].
Specifically, studies in AN adolescents have documented the
impact of family interventions that directly mobilize family
resources in tackling anorexic behaviours [16–25].
Yet these previous studies left several important questions on the
impact of FT in AN unanswered. Notably, as pointed out by
Fairburn [26], it is unclear whether the effectiveness of ‘family-
based treatment’ (e.g., the Maudsley manualized program,
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FLondon, UK [16,27]) is a consequence of parental involvement in
getting patients to eat well and maintain a healthy weight, or
whether it is rather due to major changes in intra-familial
relationships. Moreover, while there is increasing evidence
supporting the value of FT for the acute treatment of young AN
outpatients, little is known regarding its effect among inpatients.
One exception is the randomized controlled trial (RCT) study by
Russell et al. [16], which supports the effectiveness of FT in this
severely affected population, but only a small number of
participants were included (11 had individual therapy; 10 had
FT). In addition, no study has compared a program involving only
the patient and the parents with one involving the whole family.
Hence, other studies are needed to better understand the factors
accounting for treatment effectiveness of FT in severe AN cases
(e.g., young AN patients needing hospitalization).
This study [28] aimed to further investigate these questions by
determining whether the adjunction of FT intervention, focusing
on the improvement of the intra-familial dynamics, would be
associated with a better outcome than that of the usual multi-
dimensional treatment program alone (which addresses eating
disorder symptomatology (see Methods), and in which the parents
are routinely invited to participate [29].
To do so, we designed a pragmatic RCT to evaluate a
modification of our usual multidisciplinary therapeutic approach,
i.e adding a relationship-focused FT to the usual treatment. As it
has been shown that strict treatment trial protocols are associated
with low acceptance rates [30,31], both arms of the RCT retained
the flexibility of our current therapeutic outpatient program,
which is systematically adapted to each individual situation. This
procedure aimed to maximize treatment compliance and mini-
mize dropout.
Objectives
This study [28] aimed to determine whether the adjunction of
FT intervention, focusing on the improvement of the intra-familial
dynamics, would be associated with a better outcome than that of
the usual multidimensional treatment program alone (which
addresses eating disorder symptomatology) and in which the
parents are routinely invited to participate [29].
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information (see Checklist S1 and
Protocol S1).
Participants
Inclusion Criteria. 13 to 21 year-old females, with a DSM-
IV diagnosis of AN, aged under 19 at illness onset and with an AN
duration #3 years at admission to the hospital, hospitalized in our
inpatient unit for AN, living in the Paris metropolitan area, and
who had never received FT. The patient could receive appropriate
medication.
Exclusion criteria: inability to speak or read French, and/or
understand the interview questions, any metabolic pathology
interfering with eating or digestion (e.g., diabetes), or psychotic
disorder. This criterion also concerned the patients’ parents.
Recruitment and randomization
Figure 1 illustrates participants’ selection and their assignment
to the two treatment groups.
This study received approval from the Ile-de-France III Ethics
Committee and is in accordance with the terms of the Helsinki
declaration. Participants were asked to provide informed consent
after a time lapse for consideration. Written consent was
completed by the patients and their parents. Prior to inclusion in
the study, all participants were hospitalized in our care unit for life-
threatening physical and/or mental states (including BMI below
14 and or rapid weight loss and/or compromised vital functions,
severe depression, high suicide risk, chronic under-nutrition with
low weight, and failure of out-patient care). Once the patient was
admitted, the objectives of hospitalization were defined by means
of a weight contract establishing a discharge target weight
[29,32,33]. For each patient hospitalized between January 1999
and July 2002, a screening file sheet was completed by a
psychiatrist not involved in the patient’s treatment (NG or FP)
but in collaboration with the patient’s clinicians. Although each
patient and her parents were informed of the study at admission,
the inclusion and randomization occurred in the second half of
their hospital stay (i.e., half way towards their target weight), at the
time when the post-hospitalization program is defined. With
respect to the delay in reporting these results, it was mainly due to
a lack of funding.
Out of the 116 patients for whom eligibility was assessed during
the recruitment period, 40 did not meet our selection criteria (10
males; 14 for whom illness onset occurred at age 19 or older; or an
illness duration .3 years, 3 had a parent with schizophrenia; 5
were living outside the Paris area; 8 had had FT previously). Out
of the 76 eligible participants, 16 refused (21%) to participate.
Among these, 8 refused randomization, 2 refused any form of
assessment, 6 refused follow-up. The patients and parents who
refused to participate did not differ from those included with
regard to socio-demographic variables, or clinical status on entry
and at discharge (data not shown).
Allocation to one of the two parallel treatment groups (30 in
each) was performed using the SPSS randomisation program (FC).
The two groups were randomized by blocks of thirty. The result
was issued to participants in a sealed envelope at inclusion by the
psychiatrist in charge of signing the consent form (FP or
NG).Theses psychiatrists enrolled the patients and assigned them
to the intervention group. The first FT appointment was
scheduled immediately after randomization.
Treatment
Treatment as usual (TAU). Consisted in ambulatory care
initiated before hospital discharge and was tailored according to
the mental and physical state of the patient [29,32,33]. It included
individual consultations, regular interviews involving the parents,
and, if required, individual psychotherapy with another therapist.
At each appointment, the psychiatrist conducted clinical
investigation of the patient’s mental state, eating habits, medical
condition, and psychosocial environment. In addition, the
psychiatrist provided support, coordinated services (e.g., general
practitioner, psychotherapist, dietician or nutrionist, social worker,
and school), prescribed medication as necessary, and offered
parental support and guidance regarding conflicts they had with
their daughter. Parents were advised to be supportive but to leave
decisions about food to the adolescent and to discuss the difficulties
they observed not directly with their daughter during or after the
meal, but at the time of the consultations with the psychiatrist and
their daughter. In addition, nutritional/dietetic advice was
provided to the patients who were not gaining weight or not
gaining sufficient weight.
Family therapy (FT). Was designed by our team as one
component of a multi-dimensional outpatient care program
[28,34–36]. We considered AN as a disorder resulting from
multidimensional pathways [37,38]. In interaction with premorbid
personality or predispositions, the intra-familial dynamic was
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maintenance of the patient’s eating problems [39].
The main aims of FT were:
1. To construct and maintain the therapeutic alliance;
2. To identify areas of individual responsibility and clarify inter-
generational boundaries;
3. To promote abilities to protect, contain and provide support to
the family;
4. To enable appropriate expression and management of conflict;
5. To enable the family to rediscover its own resources and
strengths;
6. To restore a collective sense of family identity;
7. To develop the patient’s autonomy.
Accordingly, FT focused not only on issues in the here-and-
now, but also on unresolved issues from the past, as well as on
expectations of how these might impact the future. Sessions
focused on the familial dynamic as a whole and did not address
eating behaviors directly (which were addressed by the reference
psychiatrist). The sessions included the patient, her parents, and
her siblings if they were over the age of 6 and living in the home.
They lasted approximately 1 h30 mn and took place every three
or four weeks. To optimize outcome, the frequency of sessions was
flexible [20]. FT was proposed for a period of 18 months.
Treatment integrity. Two co-therapists (IK,RL) jointly
conducted the entire FT, so that the approach was consistent.
The psychiatrist and psychologist involved in the study had more
than four years of experience in the outpatient care of AN
adolescents. In addition, the family therapists attended weekly
meetings with the reference psychiatrists and other practitioners,
during which forthcoming situations in the families were discussed.
To ensure that the therapies were running satisfactorily, further
meetings were programmed every two to three months with the
research team members and the family therapists. In this way, the
consistency of follow-up was verified.
Assessment and Procedure
The following evaluations were conducted at the time of
randomization and 18 months later (see [28] for further details) in
the Institut Mutualiste Montsouris department of psychiatry (Paris
France):
– the Mini-Neuropsychiatric Interview (MINI, [40]);
– the Global Outcome Assessment Scale (GOAS, [41,42]);
– the Eating Disorder Inventory (EDI, [43,44]);
– the Weissman’s Social Adjustment Scale (SAS, [45,46]).
In addition, BMI (kg/m
2), menstrual status, contraceptive use
and the number of hospitalizations in the course of follow-up were
recorded.
Regarding weight status assessment, in view of the patients’ age,
we considered the Ideal Body Weight (IBW) (which is classically
defined as the average body weight of the general population over
Figure 1. Flow chart of the randomized control trial. TAU: treatment as usual; TAU+FT: treatment as usual and family therapy.
doi:10.1371/journal.pone.0028249.g001
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Hence, to take the ages of our patients into account, we referred to
the INSERM (French National Institute for Health and Medical
Research) weight curves for the French female population [47], in
which a BMI,10
th percentile indexes AN [48]. We defined the
outcome categories as follows [16,49]: 1) Good outcome : weight
.10
th BMI percentile and regular menstruation; 2) Intermediate
outcome: .10th BMI percentile but amenorrhea (i.e., the absence
of menstruation for at least the past three months); 3) Poor
outcome: weight ,10th BMI percentile and/or presence of
bulimic symptoms.
At 18 months, in case of contraceptive use, subjects with a
BMI,10
th percentile were conservatively rated as presenting
amenorrhea (8 participants).
To ensure comparability we used the methodology recom-
mended by Russell et al. [16], and pooled the Good and
Intermediate outcome categories.
The evaluators, but not participants, nor the therapists, were
blind to randomization. The interviews were conducted by one
psychologist and two psychiatrists previously trained in the
administration of the above-mentioned instruments. Each patient,
her parents and siblings were assessed individually at inclusion and
at 6, 12 and 18 months after inclusion. The patients and their
parents were evaluated by two different interviewers (see [28]).
Drop-outs were restricted in number by systematic postal or
telephone recall by the research team, the psychiatrist, or the
family therapists. One patient refused follow-up (Figure 1).
Immediately after each evaluation, a dual check procedure was
applied to the files obtained, enabling verification of the
exhaustiveness of questionnaire completion. Thereafter, the
evaluators conducted qualitative checks with the family’s clinicians
and, when required, the patients’ medical charts. Outcome
category scoring was conducted by the patient’s interviewer, and
then discussed with and validated by the coordinating psychiatrist
(NG).
Data Analysis
Power/Effect size calculation. Sample size estimation was
calculated according to the Casagrande & Pike method [50] and
based on RCT data on AN adolescent inpatients available at the
time when the study was designed (i.e. in 1997) [16]. The expected
proportion of Good or Intermediate outcomes was set to 90% in
the TAU+FT group and 40% in the TAU group. With a type one
error (2-sided) and a type two error equal to 0.05, the sample size
estimates was 50. In line with the study by Russell et al., who
reported 17% participants lost to follow-up [16], 10 additional
participants were added. Thus a sample size of 60 participants was
planned (30 in each arm; Figure 1). The recruitment procedure
ended when this number was reached.
Evaluation criteria at 18 months after inclusion. The
primary outcome criterion was the Morgan and Russell outcome
category (good or intermediate outcome versus poor outcome) at
18 months.
The secondary outcome indicators were the GOAS total score,
AN symptoms or their consequences (BMI, amenorrhea, EDI
scores), social adjustment and the number of hospitalizations in the
course of follow-up. The effect size was evaluated for qualitative
variables by the odd ratio and its confidence interval as
recommended by Fleiss et al [51] and for quantitative variables
by Cohen’s d test.
Between-group comparisons. Treatment groups were
compared on socio-demographic and clinical characteristics at
baseline and at 18 months of follow-up.
Completeness of follow-up data. Fifty-six participants were
seen at 6 months, 49 at 12 months, and 55 at 18 months.
Five were not seen at 18 months: 2 in the TAU group and 3 in
the TAU+FT group. Of these 5 participants, only one was
completely lost to follow-up, 2 were seen only at 6 months, and 2
were seen for the last time at 12 months. Missing data were
modeled using the Last Observation Carried Forward (LOCF)
procedure, which enabled the inclusion of 59 participants (29
TAU; 30 TAU+FT).
We first realized Intention to Treat Analyses (ITTA) and then
Per Protocol Analysis (PPA). For the ITTA, randomized patients
who didn’t receive any treatment were included in the analyses
and these patients were followed up in the trial. For PPA, in line
with Russell’s et al. trial [16], only those who attended more than
three sessions of FT were considered in the analyses. Accordingly,
53 received the treatment provided for in the protocol (Figure 1).
Among the TAU+FT participants, 4/30 (13.3%) did not receive
FT (#3 FT sessions). Conversely, 2/30 of the TAU participants
(6.7%) did in fact receive FT prescribed by there psychiatrist
(outside the trial) due to a context of family crisis; 1 was lost to
follow-up (Figure 1). Therefore, the PPA compared 27 TAU with
26 TAU+TF.
Analyses. The two treatment groups were compared at 18-
months of follow-up with an alpha risk of 0.05 for two-sided tests.
The Chi
2 or Fisher Exact Probability tests were used for the
categorical variables. Either Student t-tests or Mann-Whitney tests
were used (as appropriate) for the continuous variables. Finally, we
used matched series Student tests for intra-group comparisons
exploring the evolution of quantitative criteria, and Mac Nemar
tests for qualitative variables between inclusion and 18-months of
follow-up. All tests were two-sided. Analyses were performed using
SPSS 11.
Results
Participant characteristics
Descriptive statistics of the 60 AN participants are presented in
Table 1. There were 5 AN purging subtype in the TAU+FT
group and 3 in the TAU group (no group effect, p=.71). At the
start of the study, all the participants were on amenorrhea and
the TAU and TAU+FT groups were comparable. The mean
BMI at admission clearly indicates the seriousness of their
condition (i.e., much lower than the third percentile: 16.23 kg/
m
2 for 16 to 16.4 year-old [47]). Both groups had a mean BMI at
discharge over the 10
th percentile (i.e., 17 kg/m
2 for16.5 to 16.9
year-old [47]). A quarter of the participants had been previously
hospitalized for AN: 11participants had one previous hospital-
ization, 1 was previously hospitalized twice, 3 had three previous
hospitalizations. The two groups were comparable in terms of
comorbid mood and anxiety disorders (i.e., major depressive
disorder, social phobia, panic disorder, agoraphobia, obsessive
compulsive disorder, post traumatic stress disorder; details
available on request from the authors). Importantly, on average,
the participants received 18.9 (67.3) psychiatric consultations,
including 6.5 (64.6) parental consultations in 18 months, with no
between-group differences (p=0.20). In addition, 14 participants
were treated with individual therapy (7 in each group) and
received, on average, 23.4 (623.03) sessions; there was no
significant difference (p=0.22). The TAU+FT participants
attended an average of 11.8 (65.7) FT sessions. The total
number of treatment sessions (consultations, FT, individual
therapy) did not differ between the two groups (TAU:
27.2612.7; TAU+FT: 33.7624.6; p=0.55).
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Between inclusion and 18–months of follow-up, the overall
sample showed significant improvement for all the parameters
considered: the MR outcome score, the GOAS score, the EDI and
SAS total scores, the BMI and menstrual status (Detailed results
available on request from the authors).
Primary Outcome
The proportion of patients who belong to the Good and
Intermediate Outcome category was more important in the group
treated with adjunctive family therapy (Table 2). In terms of odds
ratio, the TAU+FT participants achieved Good or Intermediate
outcome 3.2 times as often as those from the TAU group in the
whole group (ITTA: p=0.054) and 4.9 times as often as those in
the restraint group (PPA: p=0.013) (Table 2). Among the
participants with a Good or Intermediate outcome (17/59), more
than half (10/17) met the criteria for Good outcome.
Secondary Outcome criteria
- The GOAS total (Table 3) and sub-scale scores (details
available on request from the authors) did not differ between the
two groups.
- The proportion of patients who achieved a healthy weight
(BMI$10
th percentile) and resumed menstruation was more
important in the TAU+FT group (Table 3).
- The TAU+FT participants achieved a healthy weight about 3
times as often as those from the TAU group in the whole group
(ITTA: p=0.044) (Table 3).
Figure 2 illustrates the proportion of patients with a BMI above
the 10
th percentile at the end of the follow-up period. Overall,
BMI increased significantly (n=59: 16.961.09 to 17.662.3;
t=22.36,df=58, p=0.021). Nevertheless, the gap between the
two treatment groups began to widen significantly at 12 months of
treatment and remained at 18 months.
When each group was considered separately, only the TAU+FT
group showed a significant evolution in average BMI (30
TAU+FT: 17.062.0 to 17.862.1, t=22.11, df=29, p=0.044;
29 TAU: 16.961.0 to 17.462.4, t=1.27 df=28, p=0.22).
- The TAU+FT group presented amenorrhea significantly less
often (OR =0.3; p =0.027) than the TAU group (19/29)
(Table 2).
- We observed no significant group effect for the EDI total
(Table 3) and sub-scale scores (details available on request from the
authors).
- Mean SAS scores (Table 3) did not differ between the two
treatment groups (p.0.05).
- Overall, 28/59 (47.5%) of the patients were re-hospitalized at
least once for AN or another psychiatric disorder. Although this
percentage was greater in the TAU (55.17%; i.e., 16/29) than in
the TAU+FT (40%; i.e., 12/30) group, the difference did not
reach statistical significance (Table 3).
Discussion
The present RCT study assessed the therapeutic effectiveness of
the adjunction of family therapy (FT), focusing on the family
dynamics, to the usual outpatient treatment (TAU) of severely ill
AN adolescents. Our hypothesis was that, relative to TAU alone,
TAU+FT would improve global outcome, AN symptoms, social
adjustment and would reduce the frequency of re-hospitalization
at 18 months of follow-up.
We showed that the proportion of patients who belong to the
Good and Intermediate Outcome category was more important in
the group treated with adjunctive family therapy (between 22.8%
and 31.3%, depending on the ITTA or PPA analyses). In other
terms, patients treated with adjunctive family therapy were 3 to
4.9 times more likely to belong to the Good and Intermediate
Outcome category [49]. Specifically, the proportion of patients
who achieved a healthy weight and resumed menstruation was
Table 1. Patients Characteristics at inclusion.
All (n=60) TAU+FT (n=30) TAU (n=30) t tests or x2; df P
Age at onset of disorder: years, mean (SD) 14.8 (1.6) 14.7 (1.7) 15.0 (1.5) 20.64; 58 .52
Age at inclusion: years, mean (SD) 16.6 (1.6) 16.4 (1.7) 16.6 (1.7) 20.27; 58 .79
AN duration: months, mean (SD) 16.6 (6.8) 17.1 (8.3) 16.1 (5.2) 0.54; 58 .59
Minimum BMI: kg/m
2, mean (SD) 13 (1.1) 12.9 (1.1) 13.1 (1.2) 20.91; 59 .37
BMI at admission: kg/m
2, mean (SD) 13.6 (1.1) 13.5 (1.0) 13.7 (1.3) 20.87; 58 .39
BMI at inclusion: kg/m
2, mean (SD) 16.9 (1.1) 17.0 (1.2) 16.9 (1.0) 0.36; 58 .72
BMI at discharge: kg/m
2, mean (SD) 17.5 (1) 17.6 (1.1) 17.5 (0.9) 0.46; 58 .65
% of ABW at admission: mean (SD) 64.2 (5.5) 63.5 (5.3) 64.9 (5.7) 20.97; 58 .33
% of ABW at inclusion: mean (SD) 83.6 (5.2) 83.9 (5.6) 83.3 (5.0) 0.93; 58 .70
% of ABW at discharge: mean (SD) 86.6 (4.9) 86.9 (5.3) 86.2 (4.5) 0.52; 58 .60
Duration of hospitalization: weeks, mean (SD) 21 (13.9) 22.4 (16.1) 19.4 (11.5) 0.82; 58 .41
GOAS: Global Score, mean (SD) 4.3(1.1) 4.3 (1.1) 4.3 (1.2) 20.16; 58 .87
EDI: Global score, mean (SD) 60.7(35.1) 61.3 (36.2) 60.2 (34.6) 0.12; 58 .90
SAS: Global score, mean (SD) 2.6 (0.6) 2.6 (0.6) 2.6 (0.6) 20.11; 58 .91
Previously hospitalized: No (%) 15 (25.0) 8 (26.7) 7 (23.3) 0.09; 1 .77
Drop-out (below discharge target weight): No (%) 12 (20.0) 5 (16.7) 7 (23.3) 0.42; 1 .52
Family status: Not intact, No [%] 9 [15.0] 3 [10.0] 6 [20.0] -; 1 .47
ABW: Average body weight [59]; AN: anorexia nervosa; BMI: body mass index; EDI: Eating disorders inventory; GOAS
: Global Outcome Assessment Scale; SAS: Social
Adjustment Scale; SD: standard deviation; TAU: treatment as usual; TAU+FT: treatment as usual and family therapy; No: number; % percentage.
doi:10.1371/journal.pone.0028249.t001
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therapy (respectively 25.8% and 28.9%). In other terms, over 3
times more AN adolescents achieved a healthy weight and
resumed menstruation. However, we found no differences for
subjective evaluations of eating behaviors and attitudes, social
adjustment, or for relapses.
We found two main results. First, in AN adolescents, adding
family therapy (including parents and siblings), with a specific
focus on intra-familial dynamics (and not on eating behaviors), to
an established integrative multi-disciplinary outpatient treatment,
significantly improved the outcome at 18 months of follow-up.
This finding suggests that a treatment targeting intra-familial
dynamics has a specific effect. Our study design made it possible to
rule out the hypothesis that the key ingredient for family therapy
effectiveness in AN is that it places ‘‘greater emphasis on getting patients
to eat well and maintain a healthy weight’’ (see [26], page S27).
Moreover, our results are in line with those of Pike et al. [52] who
showed that cognitive behaviour therapy in post-hospitalisation
treatment of AN adult patients is significantly more effective in
improving outcome and preventing relapse than nutritional
counselling alone.
Second, we showed that weight and menstruation normalization
occurred significantly more often in the FT group, despite the fact
that these symptoms were not specifically targeted during the
therapy sessions. This finding has a critical clinical implication, as
long illness duration has been associated with higher mortality
rates [53], and lasting denutrition and amenorrhea have been
linked to severe somatic complications (such as osteopenia or
osteoporosis [14]).
In the literature, only six studies in AN adolescents have
compared FT to another treatment. These studies compared the
contribution of FT to that of individual therapy [16,17,21,22,54],
or compared two types of FT intervention [18,19,54,55], or
compared two FT durations [23,24]. Overall, these studies suggest
that: FT participants have a better outcome; conjoint and
separated FT have similar effects; FT of six or 12 months’
duration have similar effect.
Across all these studies, between 60 and 95% of patients
achieved a good or intermediate outcome and continued to
improve during follow-up. Here, this was the case for 46.2% of the
participants treated with family therapy (versus 14.2% among the
treatment as usual participants). Several factors could account for
this discrepancy, such as the use of different criteria for
hospitalization as well as variations in referral and recruitment
procedures.
The most direct comparison is with the study by Russell et al.
[16], which included adolescents with similarly low weights on
admission to hospital (around 65% ABW), similar duration of
illness (1.2–1.5 years) and high levels of previous treatment. Yet
several arguments suggest a possible difference in illness severity
between our sample and that of Russell et al. First, whereas these
authors exclusively included patients who agreed to hospitalization
and who completed the inpatient program, we included numerous
adolescents who had refused care at the time of admission but who
were hospitalized by their parents (i.e., they were minors). Second,
we did not exclude participants who had not reached their target
weight when they were discharged from hospital (20% of our
sample). Finally, in the Russell et al. study [16], FT participants
had a significantly shorter hospital stay (8.8 weeks) than those in
the individual therapy group (12.1 weeks). This could be an
indirect indicator of a selection bias towards participants
experiencing lesser difficulties in their FT group.
Table 2. Global Outcome at 18 months.
TAU+FT TAU x2; df p
Absolute effect
size (95% CI)
Relative effect
size OR (95% CI)
Good or intermediate MR outcome
score ITTA: (n=59), No/n. [%]
12/30 [40] 5/29 [17.2] 3.7;1 .054 22.8 (20.4;42.9) 3.2 (0.9;10,)
Good or intermediate MR outcome
score PPA: (n=53) No/n.(%)
12/26 [46.2] 4/27 [14.8] 6.2;1 .013 31.3 (6.5;51.8) 4.9 (1.3;18.3)
95% CI: 95% confidence interval; MR: Morgan and Russell; ITTA: intention to treat analysis; PPA: per protocol analysis; OR: odd ratio; TAU: treatment as usual; TAU+FT:
treatment as usual and family therapy.
doi:10.1371/journal.pone.0028249.t002
Table 3. Secondary Outcome (ITTA).
TAU+FT
(n=30)
TAU
(n=29) t or x2; df p
Absolute effect
size (95% CI)
Effect size*
(95% CI)
BMI$10th percentile, No.[%] 16 [53.4] 8 [27.6] 4.0; 1 .044 25.8 (0.76;46.7) 3 (1.0;8.9)
Amenorrhea, No.[%] 11 [36.7] 19 [65.5] 4.9; 1 .027 28.9 (3.4;49.6) 0.3 (0.1;0.9)
GOAS Global Score, mean (SD) 7.6 (2.2) 7.1 (2.2) .83; 57 .41 0.5 0.23 (20.56;1.3)
EDI Total score, mean (SD) 48.2 (29.8) 47.4 (28.4) .95; 52 .92 0.8 0.03 (210.6;10.4)
SAS total score, mean (SD) 2.0 (0.8) 2.0 (0.8) 2.23; 48 .82 0 0 (2.29;0.29)
Psychiatric re-hospitalizations, No.[%] 12 [40.0] 16 [55.2] 1.4; 1 .24 0.15 (210;37.5) 1.8 (0.7;5.2)
Re-hospitalisation for AN, No.[%] 10 [33.3] 14 [48.3] 1.4; 1 .24 14.9 (29.7;37.3) 1.9(0.8;5.3)
Abbreviations: MR: Morgan and Russell; GOAS
: Global Outcome Assessment Scale; ITTA: intention to treat analysis; TAU: treatment as usual; TAU+FT: treatment as usual
and family therapy; SAS: Social Adjustment Scale; SD standard deviation; 95% CI: 95% confidence interval.
*Relative effect size: odd ratio for qualitative variables; Cohen’s d for quantitative variables.
doi:10.1371/journal.pone.0028249.t003
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compared FT to another treatment, the seriousness of the
participants’ condition was usually below that of our sample:
– The reported weights at the time of treatment inclusion (e.g,
91% of Ideal Body Weight in the study by Robin et al. [21]) are
above those of our study participants (i.e., 64.2% at admission
and 83.6% at inclusion);
– The participants were younger on average by 2 to 3 years and
had shorter illness duration (i.e., inclusion criteria included an
illness duration ,1 year [22,23]) than in our study;
– Past hospitalization was also less common (e.g., half at most
had been previously hospitalized in the study by Eisler et al.
[18], versus 100% in our sample) (but see also [16]).
Hence, the question whether FT effectiveness is predicted by
severity of illness should be addressed in future studies.
With respect to the proportion of favorable outcomes, the
finding of a relatively small difference (although significant)
between our two treatment groups might also be partially
explained by the fact that, unlike the study by Russell et al.
[16], the parents here were involved in both types of treatment
with a substantial benefit. Indeed, similar small differences in favor
of FT have been observed in studies which, like the present one,
compared two modes of care involving the parents in some way
[20,21]. Future studies comparing different FT approaches should
help to address this question.
In the present study, contradicting our hypothesis, adjunctive
family therapy had no significant effect on the reduction of
relapses relative to the usual treatment (respectively 33.3% and
48.3%). Nevertheless 46.7% of the overall sample required re-
hospitalization in the course of follow-up (18 months). Although
this is higher than the 10% re-admission rates reported by the
Maudsley group [16,17], it is similar to those of other follow-up
studies of AN adolescent outpatients (e.g., 25–30% of re-
admissions after a first admission and 50–75% after subsequent
admissions [56–58]).
The main strength of the present study, which gives us
confidence in the findings, is that it was sufficiently powered, with
low participant dropout at follow-up. Nevertheless, one limitation
of this research was that we did not use a FT manual. However,
though not formally set out in a manual, our method has been
described in medical publications, journals, and training sessions
[34]. Furthermore, since only two family therapists from our team
jointly conducted the sessions, we believe that this limitation had
little impact [35]. It could also be argued that another limitation is
that the FT group received 12 additional sessions compared to the
other group. This is not in fact the case, as the total number of
treatment sessions of all kinds did not differ between the two
groups.
To our knowledge, this is the first randomized controlled trial
designed to compare two multidimensional post-hospitalization
outpatient treatment programs for adolescents with AN, which
differed solely with regard to the presence of family therapy
centered on intra-familial dynamics of the whole family.
FT was effective, although the family therapists did not directly
address eating problems, weight, and the evolution of the illness. It
yielded better progress at 18 months of follow-up in terms of global
outcome, weight and menstruation status than the standard
treatment. The additional burden of treatment in terms of time for
the family, and in terms of cost, is moderate (on average, 12
sessions of 1 h30).
Although the family therapy and therapeutic program modal-
ities set out in our protocol are somewhat different from those
described by the teams that have published their investigations on
this topic, they were found effective here. Different team cultures,
varying departmental backgrounds, and different healthcare
systems have generated many techniques to treat anorexia
nervosa. These techniques, although different, may be equally
effective and not necessarily better or worse one than another.
What is essential, in our view, is that there is a need to assess the
contribution of each technique, its prerequisites or its limitations.
Subsequent to this, it would be possible in the future to compare
these different FT techniques, with regard to their effectiveness,
but above all to determine the best indications for each. For
example, one might consider which patients would benefit more
from focusing on eating attitudes and weight during family therapy
and which would not.
The evaluation of these techniques and the determination of
their particular indications might make it possible to avoid
situations where patients ‘sink’ into prolonged periods of
malnutrition despite treatment. These difficult-to-treat cases
Figure 2. Percentages of participants with a BMI$10
th percentile. TAU: treatment as usual; TAU+FT: treatment as usual and family therapy.
doi:10.1371/journal.pone.0028249.g002
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it possible to offer patients, at the beginning of treatment, optimum
individually tailored care.
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